Associated Papers
Pan-cancer inference and validation of hypermorphic, hypomorphic and neomorphic mutations.
Tagore S et al.
Nature Genetics, 2026
41673304 (PubMed )
Supplement: 41588_2025_2482_MOESM1_ESM.pdf
Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial.
Kim KH et al.
Cancer Research and Treatment, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial).
Hwang S et al.
Esmo Open, 2025
40967067 (PubMed )
Supplement: mmc9.xlsx › Arm_____
Mutation profile and chromosomal abnormality in adenomyosis.
Suda K et al.
Reproduction (cambridge, England), 2025
40679511 (PubMed )
Supplement: supplementary_tables_1-12.xlsx › Suppl.Table_5
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
40705880 (PubMed )
Supplement: science.ads0239_data_s1_to_s6.zip › science.ads0239_data_s4.xlsx › Sheet1
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.
Sharma S et al.
Jco Global Oncology, 2025
40324118 (PubMed )
Supplement: DS1_GO-24-00587.pdf
Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.
Li J et al.
Discover Oncology, 2025
40053265 (PubMed )
Supplement: 12672_2025_2008_MOESM1_ESM.xlsx › Table_S2
Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
Yabo YA et al.
Genome Medicine, 2024
38566128 (PubMed )
Supplement: 13073_2024_1321_MOESM1_ESM.xlsx › Table_S1
Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
Yabo YA et al.
Biorxiv : the Preprint Server for Biology, 2023
36945572 (PubMed )
Supplement: media-2.pdf
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW et al.
Molecular Oncology, 2023
36892268 (PubMed )
Supplement: MOL2-17-2000-s008.pdf
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
36694946 (PubMed )
Supplement: MOL2-17-1844-s003.xlsx › 2a.Studied_gene
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
Hutchinson KE et al.
Genome Medicine, 2023
37101291 (PubMed )
Supplement: 13073_2023_1181_MOESM1_ESM.pdf
Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
Huang Q et al.
Bmc Medical Genomics, 2022
35778737 (PubMed )
Supplement: 12920_2022_1297_MOESM4_ESM.pdf
Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.
Aoyagi Y et al.
Plos One, 2022
35358259 (PubMed )
Supplement: pone.0266112.s001.xlsx › Patients
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
Jin N et al.
The Journal of Clinical Investigation, 2021
IDH1 and IDH2 Mutations in Colorectal Cancers.
Huang J et al.
American Journal of Clinical Pathology, 2021
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
Sun H et al.
Nature Communications, 2021
34429404 (PubMed )
Supplement: 41467_2021_25177_MOESM8_ESM.xlsx › Sheet1
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Takayanagi D et al.
Cancers, 2021
33802174 (PubMed )
Supplement: cancers-13-01215-s001.zip › Supplymentary_files › Supplymental_table.xlsx › TableS2
Landscape of Genomic Alterations in IDH Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor.
Yan Y et al.
Jco Precision Oncology, 2020
The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.
Lombardo R et al.
Frontiers in Oncology, 2020
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C et al.
Jama Oncology, 2019
TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA et al.
Acta Neuropathologica Communications, 2018
30333046 (PubMed )
Supplement: 40478_2018_613_MOESM3_ESM.xlsx › Sheet1
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Liu D et al.
Nature Communications, 2017
29259186 (PubMed )
Supplement: 41467_2017_2320_MOESM1_ESM.pdf
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis.
Yi Z et al.
Scientific Reports, 2017
28729728 (PubMed )
Supplement: 41598_2017_6327_MOESM1_ESM.pdf
Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.
Subbiah IM et al.
Oncoscience, 2017
Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM et al.
Oncotarget, 2016
27590521 (PubMed )
Supplement: oncotarget-07-64071-s002.xlsx › Table_S4_diagnostic_mutations
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS et al.
Cancer, 2016
Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.
Hou W et al.
Oncology Letters, 2014
CanDrA: cancer-specific driver missense mutation annotation with optimized features.
Mao Y et al.
Plos One, 2013
24205039 (PubMed )
Supplement: pone.0077945.s001.xls › Table_S10
Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.
van de Geer WS et al.
Neuro-oncology Advances, 0
35047820 (PubMed )
Supplement: vdab177_suppl_supplementary_data.xlsx › Figure5
Select a paper to view details